New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
08:35 EDTKERXKeryx Zerenex phase 2 data presentation selected for Kidney Foundation meeting
Keryx Biopharmaceuticals announced that Phase 2 clinical results of Zerenex in non-dialysis dependent chronic kidney disease patients with elevated serum phosphorus and iron deficiency anemia has been selected as a Late Breaking oral presentation at the National Kidney Foundation 2014 Spring Clinical Meeting, taking place April 22-26. This presentation, entitled "Zerenex for the Treatment of Iron-Deficiency Anemia and Reduction of Serum Phosphate in Non-Dialysis Dependent CKD," will be made during the Late Breaking Session on Friday, April 25.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
11:10 EDTKERXKeryx management to meet with Oppenheimer
Subscribe for More Information
October 17, 2014
14:41 EDTKERXKeryx down 4.4% to $15.31, Orange Book cited
Shares of Keryx are lower in afternoon trading after no NCE decision in the Orange Book was updated today, as pointed out by TheStreet's Adam Feuerstein earlier on Twitter.
October 8, 2014
10:58 EDTKERXKeryx management to meet with Brean Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use